Novocure Ltd. is global oncology company, which engages in the development and commercialization of its innovative therapy. It focuses on the commercial adoption of Optune, and its Tumor Treating Fields delivery system, for the treatment of glioblastoma (GBM), and to advance programs testing the efficacy and safety of Optune in multiple solid tumor indications through clinical pipeline.
Read More…
Industry, Sector and Symbol
Industry Surgical & medical instruments
Sub-IndustryN/A
SectorMedical
Phone44-0-15-3475-6700
Debt
Price-To-Earnings
Sales & Book Value
Annual Sales$248.07 million
Profitability
Miscellaneous
EmployeesN/A
Next Earnings Date10/24/2019 (Estimated)
OptionableOptionable
Novocure (NASDAQ:NVCR) Frequently Asked Questions
What is Novocure's stock symbol?
Novocure trades on the NASDAQ under the ticker symbol "NVCR."
How were Novocure's earnings last quarter?
Novocure Ltd (NASDAQ:NVCR) issued its quarterly earnings data on Thursday, July, 25th. The medical equipment provider reported ($0.01) earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($0.07) by $0.06. The medical equipment provider earned $86.70 million during the quarter, compared to analyst estimates of $78.98 million. Novocure had a negative net margin of 13.84% and a negative return on equity of 31.80%. The firm's quarterly revenue was up 41.0% on a year-over-year basis. During the same quarter last year, the business earned ($0.17) EPS. View Novocure's Earnings History.
When is Novocure's next earnings date?
What price target have analysts set for NVCR?
7 brokerages have issued 1 year target prices for Novocure's stock. Their forecasts range from $36.00 to $91.00. On average, they anticipate Novocure's stock price to reach $66.4286 in the next year. This suggests that the stock has a possible downside of 29.1%. View Analyst Price Targets for Novocure.
What is the consensus analysts' recommendation for Novocure?
7 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Novocure in the last year. There are currently 4 hold ratings and 3 buy ratings for the stock, resulting in a consensus recommendation of "Hold." View Analyst Ratings for Novocure.
Has Novocure been receiving favorable news coverage?
News articles about NVCR stock have been trending negative this week, InfoTrie Sentiment Analysis reports. The research group scores the sentiment of news coverage by monitoring more than six thousand news and blog sources in real-time. The firm ranks coverage of publicly-traded companies on a scale of negative five to positive five, with scores closest to five being the most favorable. Novocure earned a coverage optimism score of -2.3 on InfoTrie's scale. They also assigned media coverage about the medical equipment provider a news buzz of 0.0 out of 10, indicating that recent news coverage is extremely unlikely to have an impact on the company's share price in the near term. View News Stories for Novocure.
Are investors shorting Novocure?
Novocure saw a increase in short interest in the month of July. As of July 31st, there was short interest totalling 5,283,500 shares, an increase of 7.4% from the June 30th total of 4,917,400 shares. Based on an average daily volume of 754,600 shares, the short-interest ratio is presently 7.0 days. Currently, 7.2% of the company's stock are sold short. View Novocure's Current Options Chain.
Who are some of Novocure's key competitors?
Some companies that are related to Novocure include FRESENIUS SE &/S (FSNUY), ResMed (RMD), Teleflex (TFX), DexCom (DXCM), Insulet (PODD), ABIOMED (ABMD), Hill-Rom (HRC), Haemonetics (HAE), Integra Lifesciences (IART), Penumbra (PEN), Globus Medical (GMED), Cantel Medical (CMD), ICU Medical (ICUI), Tandem Diabetes Care (TNDM) and NuVasive (NUVA).
What other stocks do shareholders of Novocure own?
Based on aggregate information from My MarketBeat watchlists, some companies that other Novocure investors own include Chembio Diagnostics (CEMI), Prospect Capital (PSEC), Calumet Specialty Products Partners, L.P (CLMT), Two Harbors Investment (TWO), Blackrock Capital Investment (BKCC), Viper Energy Partners (VNOM), Summit Midstream Partners (SMLP), Washington Prime Group (WPG), Roper Technologies (ROP) and Rewalk Robotics (RWLK).
Who are Novocure's key executives?
Novocure's management team includes the folowing people:
- Asaf Danziger, Chief Executive Officer & Director
- Mike Ambrogi, Chief Operating Officer
- Wilco Groenhuysen, CFO & Chief Accounting Officer
- Eilon D. Kirson, Chief Science Officer, Head-Research & Development
- Uri Weinberg, Vice President-Clinical Development
Who are Novocure's major shareholders?
Novocure's stock is owned by many different of retail and institutional investors. Top institutional investors include Baillie Gifford & Co. (8.99%), Vanguard Group Inc. (6.28%), BlackRock Inc. (5.66%), Price T Rowe Associates Inc. MD (2.40%), Renaissance Technologies LLC (2.09%) and Farallon Capital Management LLC (1.22%). Company insiders that own Novocure stock include Asaf Danziger, Charles G Phillips III, Eilon D Kirson, Gabriel Leung, Michael J Ambrogi, Pritesh Shah, Todd Christopher Longsworth, Wilhelmus Cm Groenhuysen, William F Doyle and Yoram Palti. View Institutional Ownership Trends for Novocure.
Which major investors are selling Novocure stock?
NVCR stock was sold by a variety of institutional investors in the last quarter, including Vanguard Group Inc., Waddell & Reed Financial Inc., Allianz Asset Management GmbH, StepStone Group LP, TimesSquare Capital Management LLC, D. E. Shaw & Co. Inc., Rhenman & Partners Asset Management AB and Essex Investment Management Co. LLC. Company insiders that have sold Novocure company stock in the last year include Asaf Danziger, Charles G Phillips III, Gabriel Leung, Michael J Ambrogi, Pritesh Shah, Todd Christopher Longsworth, Wilhelmus Cm Groenhuysen, William F Doyle and Yoram Palti. View Insider Buying and Selling for Novocure.
Which major investors are buying Novocure stock?
NVCR stock was acquired by a variety of institutional investors in the last quarter, including Baillie Gifford & Co., BlackRock Inc., Nuveen Asset Management LLC, Price T Rowe Associates Inc. MD, Invesco Ltd., Renaissance Technologies LLC, Eagle Asset Management Inc. and Farallon Capital Management LLC. View Insider Buying and Selling for Novocure.
How do I buy shares of Novocure?
Shares of NVCR can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Novocure's stock price today?
One share of NVCR stock can currently be purchased for approximately $93.72.
How big of a company is Novocure?
Novocure has a market capitalization of $9.20 billion and generates $248.07 million in revenue each year. The medical equipment provider earns $-63,560,000.00 in net income (profit) each year or ($0.69) on an earnings per share basis. View Additional Information About Novocure.
What is Novocure's official website?
How can I contact Novocure?
Novocure's mailing address is NO. 4 THE FORUM GRENVILLE STREET, ST. HELIER Y9, JE2 4UF. The medical equipment provider can be reached via phone at 44-0-15-3475-6700 or via email at [email protected]
MarketBeat Community Rating for Novocure (NASDAQ NVCR)
MarketBeat's community ratings are surveys of what our community members think about Novocure and other stocks. Vote "Outperform" if you believe NVCR will outperform the S&P 500 over the long term. Vote "Underperform" if you believe NVCR will underperform the S&P 500 over the long term. You may vote once every thirty days.
